BioNexus Gene Lab Corp.
BGLC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.24 | 0.78 | -0.02 | 0.05 |
| FCF Yield | -12.28% | -13.77% | -19.65% | -1.47% |
| EV / EBITDA | -12.61 | -8.60 | -1.55 | -2.32 |
| Quality | ||||
| ROIC | -10.04% | -7.92% | -7.76% | -4.03% |
| Gross Margin | 14.85% | 16.28% | 16.07% | 12.25% |
| Cash Conversion Ratio | 1.74 | 1.20 | 1.32 | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.90% | -2.67% | -3.39% | -4.53% |
| Free Cash Flow Growth | -58.94% | 8.85% | -1,029.00% | 95.54% |
| Safety | ||||
| Net Debt / EBITDA | 1.38 | 1.08 | 6.21 | 11.17 |
| Interest Coverage | 0.00 | -125.29 | -125.98 | -71.61 |
| Efficiency | ||||
| Inventory Turnover | 2.15 | 1.56 | 1.52 | 1.59 |
| Cash Conversion Cycle | 99.21 | 76.59 | 74.27 | 51.69 |